Literature DB >> 31608209

TAFRO syndrome: A case report and review of the literature.

Tieying Hou1, Jaspreet Dhillon2, Wenbin Xiao3, Elaine S Jaffe3, Amy M Sands1, Vishala Neppalli4, George Deeb5, Nan Zhang1.   

Abstract

TAFRO syndrome is a rare clinicopathologic variant of idiopathic multicentric Castleman disease characterized by Thrombocytopenia, Ascites (anasarca), myeloFibrosis, Renal dysfunction, and Organomegaly. Here, we report a case of TAFRO syndrome in an HIV-negative young Caucasian male who presented with fever, normocytic anemia, thrombocytopenia, and acute renal insufficiency. The serum interleukin-6 (IL-6) level was elevated. Chest and abdominal CT revealed bilateral pleural effusion, ascites, splenomegaly, and multiple mildly enlarged lymph nodes. An excisional biopsy of inguinal lymph node showed a few atrophic follicles and expansion of interfollicular areas by marked vascular proliferation and polytypic plasmacytosis. HHV-8 was negative. Subsequent bone marrow biopsy was normocellular with moderately increased megakaryocytes and occasional megakaryocytic emperipolesis. His signs and symptoms improved after treatment with methylprednisolone and tocilizumab (anti-IL-6 receptor antibody). Our study confirms the distinctive nature of this syndrome, which should allow for better recognition and appropriate therapy.

Entities:  

Year:  2017        PMID: 31608209      PMCID: PMC6787913          DOI: 10.1016/j.ehpc.2017.04.003

Source DB:  PubMed          Journal:  Hum Pathol (N Y)        ISSN: 2214-3300


  11 in total

1.  [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly].

Authors:  Kazue Takai; Koji Nikkuni; Hiroyuki Shibuya; Hideki Hashidate
Journal:  Rinsho Ketsueki       Date:  2010-05

2.  Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).

Authors:  Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Naoya Nakamura; Sadao Aoki; Shigeo Nakamura; Tomohiro Kinoshita; Yasufumi Masaki
Journal:  J Clin Exp Hematop       Date:  2013

3.  TAFRO syndrome or Castleman-Kojima syndrome: a variant of multicentric Castleman disease.

Authors:  Jennifer M Hawkins; Vinodh Pillai
Journal:  Blood       Date:  2015-10-29       Impact factor: 22.113

4.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

5.  Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.

Authors:  Makoto Ide; Yasunori Kawachi; Yoichiro Izumi; Kanji Kasagi; Tetsuro Ogino
Journal:  Eur J Haematol       Date:  2006-02       Impact factor: 2.997

6.  Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.

Authors:  Preetesh Jain; Srdan Verstovsek; Sanam Loghavi; Jeffrey L Jorgensen; Keyur P Patel; Zeev Estrov; Luis Fayad; Naveen Pemmaraju
Journal:  Am J Hematol       Date:  2015-04-29       Impact factor: 10.047

Review 7.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

8.  Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Authors:  Silvia Tedesco; Laura Postacchini; Lucia Manfredi; Gaia Goteri; Michele M Luchetti; Antonella Festa; Armando Gabrielli; Giovanni Pomponio
Journal:  Exp Hematol Oncol       Date:  2015-01-14

9.  TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature.

Authors:  Malorie Simons; Emmanuel Apor; James N Butera; Diana O Treaba
Journal:  Case Rep Hematol       Date:  2016-09-29

Review 10.  Idiopathic multicentric Castleman's disease: a systematic literature review.

Authors:  Amy Y Liu; Christopher S Nabel; Brian S Finkelman; Jason R Ruth; Razelle Kurzrock; Frits van Rhee; Vera P Krymskaya; Dermot Kelleher; Arthur H Rubenstein; David C Fajgenbaum
Journal:  Lancet Haematol       Date:  2016-03-17       Impact factor: 18.959

View more
  1 in total

1.  Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.

Authors:  Sylvain Raoul Simeni Njonnou; Justine Deuson; Claire Royer-Chardon; Frédéric Alain Vandergheynst; Virginie De Wilde
Journal:  BMJ Case Rep       Date:  2020-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.